Tailored Molecular and Pathophysiological Approach to COVID-19: Ambition and Need
A special issue of Current Issues in Molecular Biology (ISSN 1467-3045). This special issue belongs to the section "Molecular Medicine".
Deadline for manuscript submissions: closed (31 August 2023) | Viewed by 22973
Special Issue Editor
Interests: non-classical renin-angiotensin system; liver cirrhosis; COVID-19; renal failure; multiorgan failure
Special Issue Information
Dear Colleagues,
During this SARS-CoV-2 pandemic, significant areas of concern are, first, lack of specific therapies for severe cases of COVID-19 and, second, fear of emergence of viral variants that could make previous management strategies ineffective.
Common to all SARS-CoV-2 variants is the direct damage to the subtle mechanisms of the renin–angiotensin system that presides over a large part of systemic inflammation and hemodynamics, i.e., the damage to ACE2 (the cell membrane viral receptor) and ACE2-driven angiotensin 1–7 production. Attempts at replacing defective ACE2 or angiotensin 1–7 functions during the clinical course of COVID-19 have been common and pursued all over the world.
After two years of pandemic, a tailored and sensible approach to COVID-19 must include: a) a definition of the mechanisms of inflammatory disease that follow cellular infection; b) cognition of the most frequently found viral variants in terms of genomic and antigenic mutations; and c) identification of biomolecular viral and host targets, the latter being the non-classical renin-angiotensin system, that could be acted upon pharmacologically.
These aims warrant renewed international and multi-disciplinary efforts.
Dr. Sansoè Giovanni
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Current Issues in Molecular Biology is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2200 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- SARS-CoV-2
- COVID-19
- renin angiotensin system
- angiotensins
- ACE2
- ACE
- chymase
- neprilysin
- metallopeptidases